Available Trials

Bladder |  Breast |  Chronic Lymphocytic Leukemia |  Colorectal |  Fallopian |  Gynecological |  Head and Neck |  Leiomyosarcoma |  Liposarcoma |  Melanoma |  Multiple Myeloma |  Non-Small Cell Lung Cancer |  Nonlymphomatous Cancers |  Ovarian |  Pancreatic |  Peritoneal |  Prostate |  Renal Pelvis |  Sarcoma |  Squamous |  Transitional Cell |  Ureter |  Urethra |

Bladder

• USO 09-217
  An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office

Breast

• USO 11-158
  An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination with Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane Therapy
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office
• Mayo Clinic/Johns Hopkins MC0738
  The Effect of Antidepressants and Gabapentin on Tamoxifen Pharmacokinetics: A Prospective Study
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office
• Foundation for the National Institutes of Health I-SPY 2
  Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer: Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2
  Available at: Fairfax Office
• SIDE-OUT
  A Pilot Study Utilizing Molecular Profiling by IHC, FISH, DNA Microarray, and Reverse Phase Protein Microarray (RPMA) of Patients' Tumors to Find Potential Targets and Select Treatments, for Patients with Metastatic Breast Cancer
  Available at: Fairfax Office
• USO 09-097
  A Randomized, Phase III, Open-label Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First- or Second-line Trastuzumab plus Chemotherapy, in Subjects with HER2- positive Metastatic Breast Cancer
  Available at: Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office,  Arlington Infusion Suite

Chronic Lymphocytic Leukemia

• USO 11-078
  An Open-Label, Multicenter, Randomized Phase II Trial Comparing the Efficacy, Safety, and Pharmacokinetics of GA101 1000 MG Versus 2000 MG in Patients with Previously Untreated Chronic Lymphocytic Leukemia
  Available at: Alexandria Office,  Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office

Colorectal

• USO 11-072
  Phase 1/2 study of PX-866 and cetuximab CRC & SCCHN
  Available at: Alexandria Office,  Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office
• USO 10-101
  A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
  Available at: Alexandria Office,  Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office

Fallopian

• USO 10-293
  A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office

Gynecological

• USO 10-293
  A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office

Head and Neck

• USO 10-231
  Phase 1/2 Study of PX-866 and docetaxel in patients with solid tumors NSCLC & SCCHN
  Available at: Alexandria Office,  Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office
• USO 11-072
  Phase 1/2 study of PX-866 and cetuximab CRC & SCCHN
  Available at: Alexandria Office,  Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office

Leiomyosarcoma

• Johnson & Johnson YONDELIS ET743-SAR-3007
  A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide
  Available at: Fairfax Office

Liposarcoma

• Johnson & Johnson YONDELIS ET743-SAR-3007
  A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide
  Available at: Fairfax Office

Melanoma

• USO 10-052
  An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
  Available at: Fairfax Office,  Winchester Office,  Arlington Infusion Suite,  Arlington Office,  Gainesville Office,  Loudoun Office

Multiple Myeloma

• Bristol-Myers Squibb/Multiple Myeloma Research Foundation CA204009
  A Phase 2 Randomized Study of Bortezomib/Dexamethasone With or Without Elotuzumab in Subjects With Relapsed/Refractory Multiple Myeloma
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office
• Onyx Pharmaceuticals/Multiple Myeloma Research Foundation CMAP 2011-002
  Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients with Relapsed and Refractory Disease
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office
• Oncotherapeutics IST-CAR-516
  A Phase I/II Study of Carfilzomib as a Replacement for Bortezomib for Multiple Myeloma Patients Failing Bortezomib-containing Regimens
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office
• Multple Myeloma Research Foundation CoMMpass MMRF-11-001
  A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles
  Available at: Arlington Office,  Arlington Infusion Suite,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office

Non-Small Cell Lung Cancer

• USO 11-155
  A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in Combination with a Platinum Containing Doublet in Chemotherapy-Naive Subjects with Stage IV Adenocarcinoma of the Lung
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office
• USO 10-231
  Phase 1/2 Study of PX-866 and docetaxel in patients with solid tumors NSCLC & SCCHN
  Available at: Alexandria Office,  Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office
• USO 11-064
  A Phase II, Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared with Docetaxel in 2nd Line Subjects with Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC Stage IIIBwet-IV)
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office
• USO 09-179
  An Open-label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-based Chemotherapy versus Platinum-based Chemotherapy Alone as First-line Treatment of Patients with Recurrent or Advanced Non-small Cell Lung Cancer
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office
• USO 10-061
  A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum- Based Therapy
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office
• USO 08-035
  A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks, in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
  Available at: Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office,  Arlington Infusion Suite

Nonlymphomatous Cancers

• USO 11-107
  Screening protocol to detect tumor antigen expression required for enrollment on clinical research protocols of antibody-directed therapy
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office

Ovarian

• USO 10-293
  A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office

Pancreatic

• Gilead GS-US-324-0101
  A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
  Available at: Fairfax Office

Peritoneal

• USO 10-293
  A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office

Prostate

• USO 10-278
  A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with Metastatic Castrate-Resistant Prostate Cancer
  Available at: Fairfax Office,  Loudoun Office
• USO 09-073
  A Phase III Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone with or without Lenalidomide in Subjects with Castrate-Resistant Prostate Cancer
  Available at: Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office,  Arlington Infusion Suite

Renal Pelvis

• USO 09-217
  An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office

Sarcoma

• USO 10-237
  A Phase III multicenter, international, randomized, double-blind, placebo-controlled study of doxorubicin plus palifosfamide-tris vs. doxorubicin plus placebo in patients with front-line metastatic soft tissue sarcoma (IPM3001)
  Available at: Winchester Office,  Fairfax Office
• Johnson & Johnson YONDELIS ET743-SAR-3007
  A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide
  Available at: Fairfax Office

Squamous

• USO 11-072
  Phase 1/2 study of PX-866 and cetuximab CRC & SCCHN
  Available at: Alexandria Office,  Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office

Transitional Cell

• USO 09-217
  An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office

Ureter

• USO 09-217
  An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office

Urethra

• USO 09-217
  An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
  Available at: Arlington Infusion Suite,  Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Winchester Office